|
|
GLA-SE |
|
Vaxjo ID |
163 |
|
Vaccine Adjuvant Name |
GLA-SE |
|
Adjuvant VO ID |
VO_0005420
|
|
Description |
TLR4 agonist glucopyranosyl lipid A (GLA) in a stable oil-in-water emulsion (SE) formulation that induces a Th1 response |
|
Stage of Development |
Clinical Trial |
|
Location Licensed |
US (AAHI) |
|
Host Species for Testing |
Human |
|
Second Host Species for Testing |
Mouse |
|
Components |
GLA |
|
Storage |
2-8C |
|
Preparation |
stable oil in water emulsion |
|
Function |
Type: TLR agonist vaccine adjuvant. Target Receptor: Toll-like receptor 4 (TLR4). Induces Th1-biased immune profile Induces TFH responses in neonatal mice, innate immune activation |
| References |
(Soza, 2024): Vaccine Adjuvant Compendium - VAC [https://vac.niaid.nih.gov/view?id=62]
Duthie et al., 2016: Duthie MS, Favila M, Hofmeyer KA, Tutterrow YL, Reed SJ, Laurance JD, Picone A, Guderian J, Bailor HR, Vallur AC, Liang H, Mohamath R, Vergara J, Howard RF, Coler RN, Reed SG. Strategic evaluation of vaccine candidate antigens for the prevention of Visceral Leishmaniasis. Vaccine. 2016; 34(25); 2779-2786. [PubMed: 27142329].
Semmes et al., 2020: Semmes EC, Chen JL, Goswami R, Burt TD, Permar SR, Fouda GG. Understanding Early-Life Adaptive Immunity to Guide Interventions for Pediatric Health. Frontiers in immunology. 2020; 11; 595297. [PubMed: 33552052].
|
|
